Home/Filings/4/0001209191-21-024242
4//SEC Filing

Quan Venture Fund II, L.P. 4

Accession 0001209191-21-024242

CIK 0001807120other

Filed

Mar 31, 8:00 PM ET

Accepted

Apr 1, 6:25 PM ET

Size

11.2 KB

Accession

0001209191-21-024242

Insider Transaction Report

Form 4
Period: 2021-03-30
Transactions
  • Conversion

    Common Stock

    2021-03-30+280,9914,720,830 total
  • Conversion

    Common Stock

    2021-03-30+4,439,8394,439,839 total
  • Conversion

    Series B Preferred Stock

    2021-03-30458,0160 total
    Common Stock (280,991 underlying)
  • Conversion

    Series A Preferred Stock

    2021-03-307,236,9380 total
    Common Stock (4,439,839 underlying)
Footnotes (1)
  • [F1]All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

Issuer

Design Therapeutics, Inc.

CIK 0001807120

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001750370

Filing Metadata

Form type
4
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 6:25 PM ET
Size
11.2 KB